Magenta Therapeutics surges on plans to pursue strategic options

Dianthus Therapeutics

02/02/2023 23:10

** Shares of drug developer Magenta Therapeutics Inc
 MGTA.O  surge ~55% to 87 cents, after the bell
    ** Stock among top gainers across U.S. exchanges 
    ** Co said it will explore strategic alternatives and stop
further development of its programs
    ** Strategic options may include an acquisition, merger,
business combination or other transaction - MGTA
    ** Last week, co paused dosing in its early-to-mid stage
study of blood cancer therapy MGTA-117, after a participant
experienced respiratory failure and cardiac arrest resulting in
death
    ** Stock lost 91% in 2022
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))